BioSyent Inc.
BIOYF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$193.27M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $193.27 Million |
|---|---|
| Enterprise Value | $191.52 Million |
| Annual dividend | $0.16 |
| Dividend yield | 1.26% |
| Earnings per Share | $0.8 |
| Beta | 0.63 |
| Outstanding Shares | 11,393,271 |
Return
| Return on Equity | 21.53% |
|---|---|
| Return on Assets | 16.32% |
| Return on Invested Capital | 28.19% |
Valuation & Multiples
| P/E Ratio | 19.42 |
|---|---|
| PEG | 47.15 |
| Price to Sales | 3.06 |
| Price to Book Ratio | 3.06 |
| Enterprise Value to Revenue | 3.44 |
| Enterprise Value to EBIT | 14.56 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$12.39 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 19, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$13.69 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About BioSyent Inc.
711 employees
CEO: René C. Goehrum
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iro...